CSF TDP-43: A Novel Biomarker for Limbic-Predominant Age-Related TDP-43 Encephalopathy
Fischer, A.-L.; Flosbach, F.; Root, E.; Breitbarth, M.; Goericke, M. B.; Schmitz, M.; Hermann, P.; Zerr, I.
Show abstract
Mislocalization and aggregation of transactive response DNA-binding protein 43 kDa (TDP-43) represent a neuropathological hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) and are increasingly recognized in Alzheimers disease (AD) and limbic-predominant age-related TDP-43 encephalopathy (LATE). However, the in vivo value of CSF TDP-43 as a biomarker and its relation to established markers remains unclear. We quantified CSF concentrations of TDP-43 using ELISA in 25 controls, 32 ALS, 9 probable LATE, and 24 AD patients. CSF TDP-43 levels differed significantly between groups, with the highest concentrations in LATE, exceeding both ALS and AD. ALS and AD showed intermediate, comparable increases versus controls. In parallel, conventional AD biomarkers (t-tau, p-tau, and amyloid-b) showed the expected AD-typical profile but remained largely unaltered in probable LATE, indicating a dissociation between TDP-43 an AD-type pathology. These findings identify CSF TDP-43 as a promising candidate biomarker for LATE, characterized by disproportionate elevation in the absence of AD-type biomarker changes, and neurodegeneration in aging populations.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- CSF p-tau181 Increases in Patients with Neuronal Intranuclear Inclusion Disease without Amyloid Burden 97%
- CSF Aβ38 levels are associated with Alzheimer-related decline: implications for γ-secretase modulators 97%
- Susceptibility to postmortem (co)-pathologies in antemortem atrophy-based subtypes of Alzheimer’s disease 96%
Similar papers in this journal
- Alzheimer's disease biomarker profiling in a memory clinic cohort without common comorbidities 97%
- CSF and PET biomarkers for noradrenergic dysfunction in neurodegenerative diseases: a systematic review and meta-analysis 96%
- Scalable biological-cognitive profiling for Alzheimer's disease in the population 95%
Similar papers in this journal
- Elevated plasma phosphorylated tau 181 in amyotrophic lateral sclerosis relates to lower motor neuron dysfunction 95%
- Altered brain energy metabolism related to astrocytes in Alzheimer’s disease 94%
- Temporal Modeling of Amyloid and Tau Trajectories in Alzheimer's Disease using PET and Plasma Biomarkers 93%